Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are new oral drugs for the therapy of
patients with type 2 diabetes mellitus (T2DM). Research in the past decade has shown that …

Many patients with heart failure have an iron‐deficient state, which can limit erythropoiesis in
erythroid precursors and ATP production in cardiomyocytes. Yet, treatment with sodium …

Complex multicellular organisms require a coordinated response from multiple tissues to
maintain whole-body homeostasis in the face of energetic stressors such as fasting, cold …

Endothelial dysfunction often precedes the development of cardiovascular diseases,
including heart failure. The cardioprotective benefits of sodium-glucose cotransporter 2 …

Chronic hyperglycemia induces pathophysiologic pathways with negative effects on the
metabolism of most substrates as well as lipids and lipoproteins, and thereby induces …

Ulcerative colitis is an idiopathic disease that is widely incident worldwide. Canagliflozin,
antidiabetic agent, exhibited significant anti-inflammatory effects in a variety of animal …

Psoriasis is a life-long immune-mediated dermatosis with thickened, reddish, and flaky skin
patches. Canagliflozin is a gliflozin antidiabetic with non-classical remarkable antioxidative …

Vascular aging, early vascular aging or supernormal vascular aging are concepts used for
estimating the cardiovascular risk at a certain age. From the famous line of Thomas …

Objective: Sodium glucose cotransporter 2 inhibitors (SGLT2-is) are antidiabetic drugs that
improve glycemic control by limiting urinary glucose reuptake in the proximal tubule. SGLT2 …

Metabolic syndrome (MetS) is a multifactorial condition that significantly increases the risk of
cardiovascular disease and chronic kidney disease (CKD). Recent studies have …